Matthew Vincent Dolan - Mar 15, 2022 Form 4 Insider Report for DEXCOM INC (DXCM)

Role
SVP Corporate Development
Signature
By: Jereme Sylvain For: Matthew V Dolan
Stock symbol
DXCM
Transactions as of
Mar 15, 2022
Transactions value $
-$928,359
Form type
4
Date filed
3/17/2022, 04:30 PM
Previous filing
Mar 10, 2022
Next filing
Sep 6, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DXCM Common Stock Sale -$419K -1.02K -11.52% $412.41 7.8K Mar 15, 2022 Direct F1, F2
transaction DXCM Common Stock Sale -$292K -686 -8.79% $425.00 7.12K Mar 16, 2022 Direct F1, F2
transaction DXCM Common Stock Sale -$218K -484 -6.8% $450.00* 6.63K Mar 17, 2022 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On December 15, 2021, Mr. Dolan adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Dolan. The shares set forth above were sold pursuant to the 10b5-1 Plan.
F2 Included in this number are 6,634 unvested restricted stock units, 2,889 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 2,048 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 1,697 of which were granted on March 8, 2020 and shall vest through March 8, 2023.